Treating Crohn's and Colitis: what matters to patients?

Researchers at University of Leicester are interviewing people with Crohn's and Colitis to find out what matters to them when it comes to being treated with advanced therapies. Advanced therapies includes biological and small molecule drugs. 

This research aims to understand what truly matters to patients like yourself when making decisions about, and undergoing treatment with advanced therapies for Crohn's and Colitis.

Advanced therapies include biological drugs, such as infliximab, adalimumab, ustekinumab, vedolizumab, and golimumab. It also includes small molecule drugs, including tofacitinib, upadacitinib and ozanimod. 

By participating in this study, you have a valuable opportunity to share your experiences and priorities related to your treatment.

The purpose of this research project is to explore the priorities, preferences, and experiences of patients with Crohn’s disease or Ulcerative Colitis or Indeterminate Colitis regarding treatment with advanced therapies. These drugs can be given in different ways, at different doses, and have different side effects. They also need different types of monitoring. But we don’t know much about what patients care about most when taking these therapies.

Through one-to-one interviews, researchers aim to understand patients’ viewpoints better. This will help ensure care is focused on what matters to patients. The hope is that this research will give patients a voice and improve shared decision making about IBD treatment.

The study involves just one 60-minute interview, which will be be held virtually or over the telephone. A researcher will ask you questions about your experiences with and opinions on advanced IBD therapy.

To take part in this study, you must be:

- diagnosed with Crohn’s disease, Ulcerative Colitis or Indeterminate Colitis
- aged 18 years or older
- currently receiving biologic therapy or small molecules
- able to communicate in English.
- UK-based

If you're not sure whether you are currently receiving biologic therapy or small molecules, please get in touch with the researcher at rh420@student.le.ac.uk.

If you are interested in taking part, or would like more information about the study, please complete the form below:

By entering your details, you are not committing to take part, but you will be redirected automatically to the study webpage. Taking part is completely voluntary and you can withdraw at any time.

This research study is NOT funded or organised by Crohn's & Colitis UK and, therefore, we cannot take responsibility for your involvement in the research.

Opportunity posted 25 January 2024

Want to get involved in research?

The best quality research happens when people with Crohn's and Colitis are involved, and you can make a difference at every stage of research.

Page
saved

This page has been saved in your personal space. Go to “My Page” to view all saved pages.

Helpline service

Helpline
Service

We know it can be difficult to live with, or support someone living with these conditions. But you’re not alone. We provide up-to-date, evidence-based information and can support you to live well with Crohn’s or Colitis.

Our helpline team can help by:

  • Providing information about Crohn’s and Colitis.

  • Listening and talking through your situation.

  • Helping you to find support from others in the Crohn’s and Colitis community.

  • Signposting you to specialist organisations.

Please be aware we’re not medically or legally trained. We cannot provide detailed financial or benefits advice or specialist emotional support.

Please contact us via telephone, email or LiveChat - 9am to 5pm, Monday to Friday (except English bank holidays).

If you need specific medical advice about your condition, your GP or IBD team will be best placed to help.

Would you like to save the changes made to this page?